UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 20, 2011
SPECTRUM PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
| Delaware | 001-35006 | 93-0979187 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 11500 S. Eastern Ave., Ste.
240, Henderson, NV |
89052 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (702) 835-6300
| Not
Applicable |
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 7.01 |
Regulation FD Disclosure.
|
On September 20, 2011, Spectrum Pharmaceuticals, Inc. issued a press release announcing that it has received approximately $25 million in proceeds from the exercise of certain warrants, contributing to a balance of nearly $160 million in cash, cash equivalents and investments as of September 16, 2011.
The foregoing description of the contents of the press release is qualified by reference to that press release, in its entirety, a copy of which is attached hereto as Exhibit 99.1 and made a part of this report.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
| Exhibit No. | Description | |
|
99.1
|
Press Release dated September 20, 2011. |
The information in this Current Report on Form 8-K is furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 20, 2011
SPECTRUM PHARMACEUTICALS, INC.
By: /s/ Brett L. Scott
Brett L. Scott
Senior Vice President and
Acting Chief Financial Officer
3
EXHIBIT INDEX
| Exhibit No. | Description | |
|
99.1
|
Press Release dated September 20, 2011. |